NCT06063746 2026-01-08
Compassionate Use of Vidutolimod
Regeneron Pharmaceuticals
No longer available
Clinical Trials
20 trialsNCT04489433 2025-12-18
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Novartis
No longer available
NCT06590480 2025-12-18
RPL-EAP-001
Replimune Inc.
No longer available
NCT03593499 2025-05-31
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Biogen
No longer available
NCT04544202 2024-11-12
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
Novartis
No longer available
NCT00419367 2022-09-22
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
Merck Sharp & Dohme LLC
No longer available
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT00535080 2021-02-18
Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
Galderma R&D
No longer available
NCT01196208 2020-09-21
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT02297529 2019-10-31
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
Amgen
No longer available
NCT02083484 2018-01-26
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Merck Sharp & Dohme LLC
No longer available
NCT03311542 2018-01-10
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
No longer available
NCT02416232 2017-08-15
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
GlaxoSmithKline
No longer available
NCT02186249 2017-02-08
CheckMate218
Bristol-Myers Squibb
No longer available
NCT01260779 2016-07-11
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
Provectus Pharmaceuticals
No longer available
NCT02147951 2016-03-01
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Amgen
No longer available
NCT01728051 2013-10-23
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
Delcath Systems Inc.
No longer available
NCT00495066 2013-06-03
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Bristol-Myers Squibb
No longer available
NCT01005537 2010-08-06
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
No longer available